DK2185175T3 - MMP-9-regulatorer og anvendelser deraf - Google Patents

MMP-9-regulatorer og anvendelser deraf

Info

Publication number
DK2185175T3
DK2185175T3 DK08789758.3T DK08789758T DK2185175T3 DK 2185175 T3 DK2185175 T3 DK 2185175T3 DK 08789758 T DK08789758 T DK 08789758T DK 2185175 T3 DK2185175 T3 DK 2185175T3
Authority
DK
Denmark
Prior art keywords
mmp
controllers
applications
Prior art date
Application number
DK08789758.3T
Other languages
English (en)
Inventor
Irit Sagi
Gabriel Rosenblum
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of DK2185175T3 publication Critical patent/DK2185175T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
DK08789758.3T 2007-08-15 2008-08-07 MMP-9-regulatorer og anvendelser deraf DK2185175T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93548607P 2007-08-15 2007-08-15
PCT/IL2008/001082 WO2009022328A2 (en) 2007-08-15 2008-08-07 Regulators of mmp-9 and uses therof

Publications (1)

Publication Number Publication Date
DK2185175T3 true DK2185175T3 (da) 2013-05-13

Family

ID=40351257

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08789758.3T DK2185175T3 (da) 2007-08-15 2008-08-07 MMP-9-regulatorer og anvendelser deraf

Country Status (14)

Country Link
US (3) US20110052572A1 (da)
EP (2) EP2185175B1 (da)
JP (1) JP2010536744A (da)
KR (1) KR20100071972A (da)
CN (1) CN102083455B (da)
AU (1) AU2008288082B2 (da)
BR (1) BRPI0814479A2 (da)
CA (1) CA2695969A1 (da)
DK (1) DK2185175T3 (da)
ES (1) ES2406105T3 (da)
IL (1) IL222302A (da)
MX (1) MX2010001657A (da)
RU (1) RU2474433C2 (da)
WO (1) WO2009022328A2 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0814479A2 (pt) 2007-08-15 2016-07-12 Yeda Res & Dev "método para regular uma atividade de metaloproteinase 9 (mm9), método para identificar um agente capaz de regular especificamente a mmp-9, método de tratar a afecção clínica mediada pela mmp-9, molécula capaz de regular especificamente uma atividade da mmp-9, anticorpo humanizado e composição farmacêutica"
JP2011517662A (ja) * 2008-03-03 2011-06-16 ダイアックス コーポレーション メタロプロテアーゼ９結合タンパク質
MA34527B1 (fr) 2010-08-27 2013-09-02 Gilead Biologics Inc Anticorps contre la metalloproteinase de matrice 9
JP5814800B2 (ja) * 2011-12-28 2015-11-17 株式会社Ｌｓｉメディエンス 神経変性疾患の検出方法
EA201491599A1 (ru) 2012-02-29 2015-05-29 Джилид Байолоджикс, Инк. Антитела к матриксной металлопротеиназе 9
JP6148729B2 (ja) 2012-07-04 2017-06-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 共有結合している抗原−抗体結合体
RU2017128512A (ru) * 2012-07-04 2019-02-15 Ф. Хоффманн-Ля Рош Аг Антитела к теофиллину и способы их применения
CN104411725B (zh) 2012-07-04 2018-09-28 弗·哈夫曼-拉罗切有限公司 抗生物素抗体及使用方法
CN111228509A (zh) 2014-01-03 2020-06-05 豪夫迈·罗氏有限公司 双特异性抗-半抗原/抗-血脑屏障受体的抗体、其复合物及其作为血脑屏障穿梭物的应用
WO2015101587A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
EP3089759B1 (en) 2014-01-03 2018-12-05 F. Hoffmann-La Roche AG Covalently linked polypeptide toxin-antibody conjugates
CA2968141C (en) * 2015-01-16 2020-08-04 Hsing-Mao CHU Molecular constructs with targeting and effector elements
US20210261971A1 (en) * 2018-06-25 2021-08-26 University Of Southern California Compositions and methods for ameliorating tissue injury, enhancing liver regeneration and stem cell therapies

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5239078A (en) 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
US5189178A (en) 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6544761B2 (en) * 1994-12-13 2003-04-08 Human Genome Sciences, Inc. Human tissue inhibitor of metalloproteinase-4
WO1997000449A1 (en) * 1995-06-14 1997-01-03 Aberdeen University Prognostic and therapeutic system for cancer
US20020015997A1 (en) * 1997-06-16 2002-02-07 Lafferty William Michael Capillary array-based sample screening
AU6511199A (en) * 1998-10-08 2000-04-26 Calbiochem Novabiochem Corporation Diagnostic assay for matrix metalloproteinase 9 and use thereof
AU2002235692A1 (en) * 2001-02-23 2002-09-04 Biophage Inc. Methods and compositions for preventing and treating neutrophil-mediated diseases
SE0102298D0 (sv) 2001-06-27 2001-06-27 Astrazeneca Ab Crystal structure of enzyme and uses thereof
US20030139332A1 (en) * 2001-07-09 2003-07-24 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
US7731648B2 (en) * 2001-07-25 2010-06-08 Aduro Biotech Magnetic nanoscale particle compositions, and therapeutic methods related thereto
EP1487343B1 (en) * 2002-03-05 2008-12-31 Board of Regents, The University of Texas System Biospecific contrast agents
DK1610678T3 (da) * 2003-04-04 2011-10-24 Yeda Res & Dev Antistoffer til inhibering af aktiviteten af MMP-2 og MMP-9
FI20040572A0 (fi) * 2004-04-23 2004-04-23 Ctt Cancer Targeting Tech Oy Matriisi-metalloproteinaasin aktiviteetin inhibiittorit
WO2006037513A1 (en) * 2004-10-09 2006-04-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with matrix metalloproteinase 9 (mmp9)
BRPI0814479A2 (pt) 2007-08-15 2016-07-12 Yeda Res & Dev "método para regular uma atividade de metaloproteinase 9 (mm9), método para identificar um agente capaz de regular especificamente a mmp-9, método de tratar a afecção clínica mediada pela mmp-9, molécula capaz de regular especificamente uma atividade da mmp-9, anticorpo humanizado e composição farmacêutica"

Also Published As

Publication number Publication date
EP2185175A2 (en) 2010-05-19
WO2009022328A2 (en) 2009-02-19
ES2406105T3 (es) 2013-06-05
US20150158953A1 (en) 2015-06-11
US20130280247A1 (en) 2013-10-24
AU2008288082B2 (en) 2013-01-10
EP2185175A4 (en) 2010-08-11
EP2581445A1 (en) 2013-04-17
US8999332B2 (en) 2015-04-07
RU2474433C2 (ru) 2013-02-10
EP2185175B1 (en) 2013-02-13
IL222302A (en) 2016-07-31
CN102083455B (zh) 2015-01-07
CN102083455A (zh) 2011-06-01
CA2695969A1 (en) 2009-02-19
AU2008288082A1 (en) 2009-02-19
RU2010108429A (ru) 2011-09-20
MX2010001657A (es) 2010-03-15
WO2009022328A3 (en) 2010-03-04
US20110052572A1 (en) 2011-03-03
EP2581445B1 (en) 2015-04-08
KR20100071972A (ko) 2010-06-29
JP2010536744A (ja) 2010-12-02
BRPI0814479A2 (pt) 2016-07-12

Similar Documents

Publication Publication Date Title
DK2185175T3 (da) MMP-9-regulatorer og anvendelser deraf
CY2015013I1 (el) Αντι-μολυσματικες πυραμιδινες και χρησεις αυτων
DK2209806T3 (da) Anti-hepcidin-antistoffer og anvendelser deraf
DK2059535T3 (da) Prlr-specifikt antistof og anvendelser deraf
BRPI0812367A2 (pt) Dispositivos interoclusais e respectivos métodos de fabrico
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
DK3292874T3 (da) Anti-mesothelin-immunkonjugater og anvendelser deraf
DK2068887T3 (da) SP35-antistoffer og anvendelser heraf
DK2139490T3 (da) Diazo-bicykliske smac-mimetiske stoffer og anvendelser deraf
DK2281006T3 (da) Tværbindingsmidler og anvendelser deraf
BRPI0817829A2 (pt) Comunicador
DK2147096T3 (da) Modificerede faktor-VII-polypeptider og anvendelser deraf
DK3348232T3 (da) Stentelement
DK2012773T3 (da) Lægemidler og anvendelser deraf
DK2185552T3 (da) Dipeptoid-prodrugs og anvendelse heraf
DK1866339T3 (da) GTR-bindende molekyler og anvendelser heraf
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK2142529T3 (da) Trpv1-antagonister og anvendelser deraf
DK2170287T3 (da) Mikropartikler omfattende PCL og anvendelser deraf
DK2114903T3 (da) Bicykliske pyrimidinoner og anvendelser deraf
DK2001556T3 (da) Thioninium-forbindelser og anvendelse deraf
DK2245032T3 (da) Folater, sammensætninger og anvendelser deraf
DK2160336T3 (da) Forbindelsesmekanisme og fremgangsmåde
DK2176284T3 (da) Lantibiotika og anvendelser deraf
DK2252688T3 (da) Syntetiske phosphodiester-oligonukleotider og terapeutiske anvendelser deraf